Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of RNA interference (RNAi) therapeutics. Founded in 2002, Alnylam has made significant strides in the development of innovative treatments for rare genetic diseases, positioning itself as a leader in the industry. With a strong operational presence in key regions, including Europe and Asia, Alnylam focuses on delivering transformative medicines that target the underlying causes of diseases. Its core products, such as ONPATTRO and GIVLAARI, are distinguished by their unique mechanism of action, offering patients new hope where traditional therapies have fallen short. Recognised for its commitment to scientific excellence, Alnylam has achieved numerous milestones, including the first-ever approval of an RNAi therapeutic, solidifying its market position as a trailblazer in the biopharmaceutical landscape.
DitchCarbon Score
How does Alnylam Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alnylam Pharmaceuticals's score of 34 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alnylam Pharmaceuticals's reported carbon emissions
In 2023, Alnylam Pharmaceuticals reported total carbon emissions of approximately 9,933,000 kg CO2e, comprising 3,529,000 kg CO2e from Scope 1, 9,933,000 kg CO2e from Scope 2, and 3,270,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions included significant contributions from business travel (3,270,000 kg CO2e), employee commuting (2,560,000 kg CO2e), and waste generated in operations (1,107,000 kg CO2e). In 2022, the company recorded total emissions of about 10,094,000 kg CO2e, with Scope 1 emissions at 4,095,000 kg CO2e, Scope 2 emissions at 10,116,000 kg CO2e, and Scope 3 emissions at 8,860,000 kg CO2e. This indicates a slight decrease in total emissions from 2022 to 2023. Alnylam has not publicly disclosed specific reduction targets or initiatives, nor have they committed to Science-Based Targets Initiative (SBTi) reduction targets. However, the company continues to monitor and report its emissions across all three scopes, demonstrating a commitment to transparency in its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 3,054,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 8,518,000 | 0,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | 3,133,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alnylam Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
